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Summary
Coffin-Lowry syndrome (CLS) is an X-linked disorder
characterized by severe psychomotor retardation, facial
and digital dysmorphisms, and progressive skeletal de-
formations. By using a positional cloning approach, we
have recently shown that mutations in the gene coding
for the RSK2 serine-threonine protein kinase are re-
sponsible for this syndrome. To facilitate mutational
analysis, we have now determined the genomic structure
of the human RSK2 gene. The open reading frame of
the RSK2 coding region is split into 22 exons. Primers
were designed for PCR amplification of single exons
from genomic DNA and subsequent single-strand con-
formation polymorphism analysis. We screened 37 pa-
tients with clinical features suggestive of CLS. Twenty-
five nucleotide changes predicted to be disease-causing
mutations were identified, including eight splice-site al-
terations, seven nonsense mutations, five frameshift mu-
tations, and five missense mutations. Twenty-three of
them were novel mutations. Coupled with previously
reported mutations, these findings bring the total of dif-
ferent RSK2 mutations to 34. These are distributed
throughout the RSK2 gene, with no clustering, and all
but two, which have been found in two independent
patients, are unique. A very high (68%) rate of de novo
mutations was observed. It is noteworthy also that three
mutations were found in female probands, with no af-
fected male relatives, ascertained through learning dis-
ability and mild but suggestive facial and digital dys-
morphisms. No obvious correlation was observed
between the position or type of the RSK2 mutations and
the severity or particular clinical features of CLS.
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Introduction
Coffin-Lowry syndrome (CLS) (MIM 303600) is a rare
syndromic form of X-linked mental retardation, with
some diagnostic features, such as skeletal abnormalities.
Typically, male patients are of short stature and exhibit
a characteristic coarse face with a prominent forehead,
orbital hypertelorism, epicanthic folds, thick lips, a thick
nose septum with anteverted nares, and irregular or
missing teeth. Their large and soft hands with lax skin
and tapering fingers are usually diagnostic features. The
most frequent skeletal changes are delayed bone devel-
opment, spinal kyphosis and/or scoliosis, and pectus car-
inatum or excavatum. There is marked variability in the
clinical expression of the disease (Coffin et al. 1966;
Lowry et al. 1971; Temtamy et al. 1975; Fryns et al.
1977; Hunter et al. 1982; Gilgenkrantz et al. 1988; Kra-
jewska et al. 1988; Young 1988; Hartsfield et al. 1993).
By using a positional cloning approach, we recently
identified the gene mutated in Xp22.2 in CLS patients
(Trivier et al. 1996). It encodes RSK2, a growth fac-
tor–regulated serine-threonine protein kinase, acting in
the ras-mitogen–activated protein kinase signaling path-
way (Blenis 1993). The human RSK2 cDNA encodes a
protein of 740 amino acids containing two nonidentical
kinase catalytic domains (Jones et al. 1988; Bjorbaek et
al. 1995).
Initial screening of the RSK2 gene in CLS patients
resulted in the identification of 11 different mutations,
8 of which were predicted to result in protein truncation;
the remaining 3 resulted in amino acid substitutions,
affecting highly conserved residues within the N-termi-
nal ATP-binding site and within two known phosphor-
ylation sites. All these mutations were predicted to have
detrimental effects on the transduction function of the
RSK2 protein, suggesting that loss of function of RSK2
is responsible for the disorder (Trivier et al. 1996).
To gain more insight into the mutational spectrum in
CLS and to see whether some genotype/phenotype cor-
relation emerges regarding either severity of the disease
or expression of uncommon clinical features, we have
determined the intron-exon structure of the human
RSK2 gene and have extended mutation screening to a
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Table 2
Intron-Exon Structure of the RSK2 Gene
EXON POSITIONa SIZE
SPLICE JUNCTIONS IN
3′ Splice Site 5′ Splice Site
1 ?–70 ? ) GCTGAGgtgagtgcagcagggcggc
2 71–126 57 cttgctgtgcttttcacagAATGGA CAAACTgtaagttaaaatattttat
2 127–243 117 cttacgtttatctcaacagGAAGAA GGAAAGgtaagtcatgagtgtgtgc
4 244–325 82 ttctgtcatttcaatatagGTTTTC TGAAAGgtaagtgctgctgctattt
5 326–406 81 tacatacaatcttttatagTTCGAG ATTATGgtaagtatgagccgtctcc
6 407–486 80 ttttcatttcttcattcagCTTTTC AAAGAGgtatataattaatctctat
7 487–593 107 aattattgttttattttagGTGATG AGAAAAgtaaggaatcatgctacta
8 594–631 38 ttttctttgtttttttcagTATACT TAACAGgtaaaaaaaaaatcctcgt
9 632–774 143 atgatatttgttttggcagATTTCG TTAATGgtaaggtttgaatttggga
10 775–845 71 ttattttgcctttctgtagTTTGAA TCTTAAgtaagtactcccttaatat
11 846–934 89 atgtggatttattatttagAGCCAA GATTAGgtaaaaattttaactaatt
12 935–999 65 gtgaatccatttttgatagGTGCAG TGGAATgtaagtatagaatgaaaac
13 1000–1102 103 ctttttttttcccctccagAAACTG CCAAAGgtaaggagaaaatgtgaaa
14 1103–1227 125 cacttcttactcttttcagATTCAC GTTCAGgtgagtggatgtctaaata
15 1228–1353 126 aatttataattttttgtagCAGTTA GTGAAGgtaaattttttttatttaa
16 1354–1443 90 ataaacatttgccttttagATTATT AAGGATgtaagtagattctttaata
17 1444–1602 159 ttgatgttgaaatttatagGTATAT CAAGGGgtaagtctttttaccactc
18 1603–1765 163 taatttgtatttcaattagGTGGTT CCAGAGgtaattgtgagagagtttg
19 1766–1841 76 aattttgcactttttctagGTTTTA TACCGGgtgagtgtataccatatgt
20 1842–1959 118 taattttattataaattagTTACAC GCAAAGgtaagtatcacttcctatc
21 1960–2101 141 tttattattcccattacagGACCTG GTAAAGgtgagcagccccatacagt
22 2102–? ? ctttatttcctttgttcagGGTGCC )
a According to the numbering used by Bjorbaek et al. (1995).
large number of CLS patients. The coding region of the
gene is divided into 22 exons. Genomic DNA from 37
unrelated patients, including 7 familial and 28 sporadic
cases (for 2 patients the status was unclear), presenting
highly suggestive features of CLS were analyzed for the
presence of mutations. Twenty-one exons, carrying 97%
of the RSK2 coding region, were explored by SSCP anal-
ysis and direct sequencing of the abnormal conformers.
Twenty-five different mutations were identified. As ex-
pected for a severe X-linked disease, we found a high
heterogeneity of mutations, widespread throughout the
coding sequence. A very high proportion appear to be
new mutations, and ∼80% are predicted to result in
truncated proteins. Evaluation of the available clinical
data from the CLS patients gives no clear indication of
correlation between genotype and phenotype.
Patients and Methods
Patients
Genomic DNAs of 37 unrelated patients with the di-
agnosis or suspected presence of CLS were screened for
a mutation. They were referred, mainly consecutively, to
the publication of the CLS gene identification (Trivier et
al. 1996), by 35 different European, American, and Aus-
tralian pediatricians or clinical geneticists. For these 37
patients, clinical information suggestive of CLS was
available, and/or a mutation was found (table 1). It is
worth noting that 23 additional patients, negative for a
mutation, were not included in the present report, since
no clinical data and no photographs have been available
on them; if clinical records can be obtained, they will
be further studied. Most (28/35; for 2 the status was
uncertain) of the 37 patients included in the present
study were sporadic cases, including the 4 females (apart
from the proband, there was no other affected male or
obvious expressing female carrier).
Intron-Exon Structure of the RSK2 Gene
DNA from two YACs (2527D1 and 4BH4) was di-
gested in two separate reaction mixtures, one withEcoRI
and one with XbaI, and the resulting fragments were
subcloned in a l ZAP vector (Stratagene) digested with
either EcoRI or XbaI. Ligation of the YAC fragments
to the l vector arms, packaging using the Gigapack III
XL packaging extract (Stratagene), and infection of Es-
cherichia coli XL1 blue strain were done according to
the supplier’s recommendations. Subclones were
screened by hybridization with several different cDNA-
derived fragments, which together covered the entire
open reading frame. Positives clones were sequenced
with exon-derived primers.
SSCP Analysis of CLS Patients
Primer sets for each exon are listed in table 2. PCR
reactions were performed in 20-ml volumes containing
Jacquot et al.: RSK2 Mutations in Coffin-Lowry Syndrome 1635
100 ng of genomic DNA template; 1# PCR buffer (Per-
kin-Elmer); 200 mM each dATP, dGTP, dCTP, and dTTP;
10 pmol of each primer; 0.3 mCi of dCTP a32P; and
0.25 U of Taq DNA polymerase (Perkin-Elmer). PCR
reactions were performed in a PTC 100 thermal cycler
(MJ Research) and consisted of 30 cycles of 94C for
10 s, the appropriate annealing temperature for each
primer pair (table 1) for 10 s, and 72C for 10 s. A final
extension reaction was performed at 72C for 5 min.
PCR products were diluted 1/5 in formamide buffer
(95% formamide/10 mM EDTA pH 8.0, 0.05% bromo-
phenol blue, and 0.05% xylene cyanol), were denatured
at 90C for 5 min, and then were cooled rapidly. For
each sample, 4 ml was loaded onto a 10% glycerol/6%
polyacrylamide gel. The gels were run at 5 W for 10–12
h at 4C. The PCR-amplified cDNA from patients with
altered migration was sequenced directly on an ABI
DNA sequencer. All sequences were determined on both
strands.
Results
Intron-Exon Structure of the RSK2 Gene
Partial sequencing of subclones derived from two
YACs, yWXD2527 and 4BH4, containing the human
RSK2 gene, and comparison with the RSK2 cDNA se-
quence allowed us to identify 21 exon-intron boundaries
interrupting the RSK2 coding region. The nucleotide and
deduced amino acid sequences of all exons were identical
to the cDNA sequence that had been reported elsewhere
(Bjorbeak et al. 1995). The sequences of the exon-intron
boundaries, as well as exon sizes, are given in table 2.
All exon-intron boundaries conformed to the GT/AG
consensus for intronic donor and acceptor splice sites.
As reagents for mutational analysis, primers were de-
signed, from the intronic sequences, to amplify each
exon from genomic DNA. For amplification of the cod-
ing sequences contained within the first exon and the
last exon, in each case one primer in the 5′ UTR (flanking
the ATG initiation codon) and one primer in the 3′ UTR
region (flanking the TAG stop codon), respectively, was
chosen. For all but exon 1, they produced a single prod-
uct of the predicted size; despite repeated trials with
different primers, no unique fragment could be obtained
for exon 1. Since chimerism of the genomic clones in
the region immediately upstream of the translation-ini-
tiation codon could not be excluded, a search for cDNA
clones extending into the 5′ UTR was initiated. No hu-
man expressed sequence tag containing 5′ UTR could be
identified by database searches. However, screening of
several human cDNA libraries by a PCR-amplified probe
corresponding to the extreme 5′ end of the coding region
resulted in the identification of one clone that extended
50 nucleotides upstream of the translation-initiation co-
don, in the 5′ direction. No differences were detected by
comparison of this additional cDNA sequence versus the
corresponding genomic sequence determined on the ba-
sis of the YAC subclone, excluding the possibility that
failure to amplify exon 1 is due to chimerism. This se-
quence was revealed to be highly GC rich, with 84%
guanines and cytosines. The primer sets used to amplify
exons 2–22 of RSK2 from genomic DNA templates are
listed, with their product sizes, in table 3.
RSK2 Mutation Analysis in CLS Patients
Exons 2–22 were amplified from the DNA of one
affected individual from each of 37 families and were
screened for mutations by means of SSCP analysis. Ab-
normal SSCP bands were found in 31 patients. Direct
sequencing of both strands of the corresponding PCR
products revealed, in 25 patients, sequence changes pre-
dicted to be disease-causing mutations. Table 4 sum-
marizes the mutations observed in this study. In 15 pa-
tients (including 9 with a mutation), polymorphisms
were identified.
Eight single-base substitutions were found at consen-
sus splice sites, in seven different introns, in eight un-
related patients (table 3). Six occur at splice-acceptor
sites, and two occur at donor sites. Two affected the
same splice-acceptor site 5′ of exon 9, one at position
2 (ArG) and the second at position 1 (GrT). All of
these mutations were unique to the present study, and
only one, the 326 1GrC mutation present in a man-
ifesting female proband (CN49) (without any affected
male in her family), has been documented elsewhere, in
one male patient (BB89; Merienne et al. 1998). The exon
organization of the RSK2 coding sequence predicts that
all but one (i.e., 3261GrC) of the splice-site mutations
will result in the alteration of the reading frame, leading
to the introduction of a premature termination codon.
The 326 1GrC mutation had previously been shown,
in patient BB89, to lead to in-phase skipping of exon 5.
Patients BB89 and CN49, sharing the 326 1GrC mu-
tation, had entirely different haplotypes around RSK2,
rendering a common ancestry highly unlikely. Seven pa-
tients with splice-site alterations represented sporadic
cases, and one patient represented a familial case. In
three sporadic cases for which DNA samples were avail-
able from the mothers of the probands, including female
patient CN49, we could demonstrate that the mutation
arose de novo.
In five patients, small deletions or insertions resulted
in a frameshift at the mRNA level (table 4); these in-
cluded three distinct 1-bp deletions (in exons 4 and 6),
a single 1-bp insertion (in exon 11), and a 5-bp deletion
(in exon 17). All these frameshift mutations, predicted
to produce a premature stop codon, were unique.
Seven nonsense mutations were characterized, in two
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Table 3
Primers for Mutation Analysis
EXON
PRIMER SEQUENCE
LENGTH
(bp)
ANNEALING
TEMPERATURE
(C)Forward Reverse
2 TGATGTGAGGTCTGTTTTGGT TTCATTTATCTATACCCTTTGTG 145 55
3 TTTGATTTTTAGCGGGAG AAGACTGGTAGCATTTCATAA 285 55
4 GCAGGGTCTTATTTTAACAA GACCTTTCAGTTTGTTTAGAC 210 55
5 AGTGGATATTACAATGTAGCA GGGAGACGGCTCATACTTA 140 55
6 TATGAATGACCTAATGTAAACC CAGGATGCATGTAAATAGACT 190 55
7 ACAGACACAAAAAGAAAATAAAT ATCATATTACATTGTATTCAACT 200 50
8 GGATGTCATTTCAGTCTTA GCCCTAATACAAGTTTTT 240 52
9 GATTAATGTCAGAACTCAAAG ACAATCTCCTTCCCCTC 265 54
10 ACACTTCTGATTATTTTGCCT CATCAAAACATCTATATTAAGGG 130 57
11 CCACCACAAAACAAATATCTACT AAAATAAAAATACAGATGCCTCC 230 61
12 TTTCAAGCAAGTTTTCATTCT GAAATAAAATTATCAGTGAATCC 125 57
13 GTATAGAATGAAAACTTGCTTG TATTTGTTGTCTTATATTTGGAT 220 55
14 CTTCTTTGTCACTTCTTACTC TATCTTACAACATTCCAAATC 230 52
15 GGCATTATGGGACTCTTCCAC GGCACTTTTAACAACAAGGGG 260 61
16 TGTATAGTTGATGAGGTTT AGACAACTGATTCAAATGA 170 47
17 GTATATGATGATGGAAAGTAT GTGTGTATGAAGATATAGAGTGG 190 56
18 AGGTCAGCACTCATCATC TAAAACATACTAATACTGCAA 315 52
19 CAACTCATAGCCTTACAAATA AAATGCTTAGGTGCTTAGAAC 180 55
20 TTTGATAGGAAGTGATACT GAGTACTTTTGAGATTACC 210 47
21 AAGAGCCATAGAAAAAGAAGC TGGAGGACCTGTGGAAAAC 245 60
22 TGTGTACGTGTGACTATCCATT GTGTGCTTGCAGGTGTCTCTC 280 60
familial cases and five sporadic cases (table 4); two of
these nonsense mutations were found in exon 5, affecting
two neighboring codons (R112X and R110X), and one
each of the remaining five were found in codons 10, 11,
17, 18, and 20. Six of these mutations occurred at CpG
dinucleotides, affecting, in each case, an arginine co-
don (R110X, R112X, R233X, R305X, R514X, and
R558X).
Although all these changes were unique in this series
of patients, the R558X mutation observed in individual
DZ34 already had previously been found in one patient,
AH72 (Merienne et al. 1998). Haplotype analysis of the
two patients DZ34 and AH72 (from France and Bel-
gium, respectively) carrying the R558X mutations con-
firmed the presence of recurrent independent mutations.
Five missense changes, which are likely to be patho-
genic, have been detected in the present study. The first
N-terminal missense mutation, located in exon 4, re-
sulted in the substitution of a phenylalanine for a valine
at position 82. The altered valine is situated one residue
beyond the putative ATP-binding site of the NH2-ter-
minal kinase domain and is highly conserved in all
known protein kinases (Hank and Hunter 1995). Un-
fortunately, no clinical data were available for the male
patient, AG89, bearing this mutation. An exchange of
a glutamine for a histidine at position 127 (exon 5) was
found in patient DX36, a sporadic male case. This his-
tidine is highly conserved, not only in all RSK members
but also in the majority of the known protein kinases
(Hanks and Hunter 1995). The mother of this patient
did not carry the mutation. A missense mutation ob-
served in exon 6 in a manifesting female patient, DX84,
involved a substitution of tyrosine for aspartate at codon
154. This aspartate residue is highly conserved within
most of the protein kinases (Hanks and Hunter 1995).
The substitution A225V, in exon 9, was observed in one
sporadic case, DG72. Alanine 225 is located two resi-
dues upstream of serine 227, which has been shown to
be a phosphorylation site critical for RSK2 catalytic
function (Fisher and Blenis 1996). In addition, protein-
database comparison showed that alanine 225 is a con-
served residue present in all known RSKs, including the
homologues identified in Drosophila and Xenopus lae-
vis. No clinical data were available for patient DG72,
who carried this mutation.
Finally, a substitution of aspartate for glycine at po-
sition 431 was observed in patient BC72. Glycine 431
is located within the putative ATP-binding site of the C-
terminal kinase domain and is conserved in all known
protein kinases (Hanks and Hunter 1995). The clinically
normal mother of this sporadic case did not carry the
mutation.
We tested for the presence of these amino acid changes
on 100 normal chromosomes, under the same SSCP
conditions, and did not find them. This further supports
the conclusion that these alterations are indeed disease
causing.
Finally, two additional sequence changes were ob-
served in the present study. A TrG transversion in exon
2, leading to the substitution of a nonpolar isoleucine
for a polar serine at codon 38, was found in five un-
related CLS patients. The same change was found once
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Table 4
RSK2 Mutations
Patient (Sex)
Type of
Mutationa
Referring
Clinician(s) Exon
Nucleotide
Change
Predicted Protein or
Splicing Alteration
Status of
Mother
DX12 (M) Sporadic Schelley 4 del296T Frameshift Noncarrier
DZ15 (M) Sporadic Bay/Sell 4 del262A Frameshift Not tested
AG89 (M) Familial Pembrey 4 244GrT V82F Not tested
DZ28 (M) Sporadic Kirkpatrick 4 244 2ArG Destroy acceptor splice site Not tested
DX36 (M) Sporadic Brookshire 5 379TrG H127Q Noncarrier
DZ26 (M) Sporadic Kress 5 328CrT R110X Carrier
BL4 (M) Familial Friedman/Berkenstadt 5 332CrT R112X Not tested
CN49 (F) Sporadic Kimberly 5 326 1GrC Destroy acceptor splice site Noncarrier
DZ11 (M) Storm/Willems 6 del451A Frameshift Not tested
DX84 (F) Sporadic Super 6 458GrT D154Y Noncarrier
AS93 (M) Sporadic Winter 6 486 1GrA Destroy donor splice site Carrier
DG72 (M) Sporadic Tariverdian 9 674CrT A225V Noncarrier
DZ12 (M) Sporadic Mills 9 632 2ArG Destroy acceptor splice site Not tested
DZ68 (F) Sporadic Crow 9 632 1GrT Destroy acceptor splice site Not tested
DZ50 (M) Sporadic Torrado 10 817CrT R223X Not tested
DZ20 (M) Sporadic Stewart 11 ins910T Frameshift Not tested
DZ47 (M) Sporadic Graf/Ptacek 11 913CrT R305X Not tested
DZ3 (M) Sporadic Schinzel 13 1000 2ArG Destroy acceptor splice site Noncarrier
BC55 (M) Sporadic David 14 1103 1GrA Destroy acceptor splice site Noncarrier
BC72 (M) Sporadic Poncin 15 1289GrA G431D Noncarrier
DZ67 (M) Crow 17 del1587TGAAA Frameshift Not tested
CU94 (M) Sporadic McDonald-McGinn 17 1540CrT R514X Carrier
DZ34 (M) Familial Delobel 18 1672CrT R558X Not tested
BG49 (M) Familial Berkenstadt 18 1764 1GrA Destroy donor splice site Not tested
DX56 (M) Sporadic Kress 20 1934GrA W645X Not tested
a For definition of sporadic cases, see Patients and Methods.
in 100 control chromosomes, suggesting that the variant
is a likely nonpathogenic polymorphism. Finally, a
CTArCTC sequence variant at codon 266, which pre-
dicts no amino acid changes, was detected in 10 unre-
lated patients. Both of these changes have been previ-
ously reported, in non-CLS patients (Bjorbaek et al.
1995).
Discussion
To enable the full range of RSK2 mutations to be
identified, we have determined the genomic organization
and intron-exon boundaries of the human RSK2 gene.
Our preliminary results show that 2 kb of the 3′ UTR
are present in exon 22 and suggest that the whole 5′
UTR is present in exon 1. However, further studies on
additional genomic and cDNA clones are necessary to
complete this analysis. The RSK2 gene was screened for
mutations, by means of SSCP analysis followed by direct
sequencing of variant bands. We were unable to specif-
ically amplify the first 70 bp of the coding region from
exon 1, although several attempts were made with dif-
ferent primer pairs and amplification conditions. We sus-
pect that the high GC-rich content of the region im-
mediately upstream of the ATG translation-initiation
site, in combination with the AT-rich composition of the
first intron, generates conditions unfavorable for effi-
cient PCR. Tests with different polymerases, PCR con-
ditions, and primers are ongoing.
In the analysis of 37 patients with clinical features
suggestive of CLS, 25 distinct mutations were found,
including 8 splice-site alterations, 7 nonsense mutations,
5 frameshift mutations, and 5 missense mutations. All
were unique to this series of patients, and only two
(R558X and 326 1GrC) had been documented else-
where, both in one family (Trivier et al. 1996; Merienne
et al. 1998).
The seven nonsense mutations and the five insertion/
deletion mutations are all expected to produce non-
functional truncated proteins. The same holds true for
six of the seven splice-site alterations. All these latter
mutations hit either the conserved GT splice-donor dinu-
cleotides or the conserved AG splice-acceptor dinucleo-
tides and should thus lead to either exon skipping or
activation of a cryptic splice site. Skipping is predicted
to lead, in all but one case (3261GrC), to a frameshift
in the misspliced exon sequences, resulting in protein
truncation. The 326 1GrC was shown to result in in-
phase skipping of exon 5 in a previously reported patient
carrying the same mutation. However, western blot anal-
ysis, using an antibody directed against the RSK2 C-
terminus, failed to reveal RSK2 in this patient, which
strongly suggests that the resulting internally deleted
protein is unstable (Merienne et al. 1998). Clinical data
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suggest that the extent of protein truncations does not
correlate with the severity of the phenotype. Indeed, pa-
tients with various truncating mutations, including a
4-bp insertion (2105insGTGC) at the very 3′ end and a
stop mutation in exon 5 (R112X), show very similar
severe mental retardation and skeletal changes. We spec-
ulate that truncated proteins are unstable, although this
cannot be assessed, since no antibody for the N-terminal
region is available.
Five missense changes, which are likely to be patho-
genic, have been detected in this study. The glycine res-
idue at position 431, located within the C-terminal ki-
nase domain, is important for ATP binding (Hanks and
Hunter 1995), and Valine 82 is located two residues
downstream of the N-terminal ATP-binding motif.
Fisher and Blenis (1996) have identified the N-terminal
domain as being responsible for substrate phosphory-
lation and have shown that the N-terminal domain is
necessary for autophosphorylation and, thus, for opti-
mal enzyme activity. Therefore, both the G431D mu-
tation and the V82F mutation are predicted to have det-
rimental effects on the transduction function of RSK2.
Unfortunately, no cell lines were available to test the
RSK2 kinase activity in the patients with these muta-
tions. However, we have shown elsewhere that the sub-
stitution of another highly conserved glycine residue
from the N-terminal ATP-binding site (G75V) dramat-
ically impairs RSK2 phosphotransferase activity (Trivier
et al. 1996). The A225V missense is two residues up-
stream of an autophosphorylation (serine 227) site im-
portant for maximal enzyme activity (Zhao et al. 1995).
Finally, two missense mutations in exons 5 and 6,
H127Q and D154Y, affect residues conserved in all pro-
tein kinases, suggesting an important functional role. In
addition, both mutations were shown to occur as de
novo mutations. The biochemical effect of these two
mutations is less evident, since they occur in protein
domains with no predicted function. However, it could
be hypothesized that a conformational change affects
the protein catalytic function, since, in both cases, a
charged amino acid is replaced by a polar noncharged
residue in the N-terminal kinase domain. It would be of
interest to study the effect that these missense mutations
have on the biochemical activity of RSK2.
Two additional sequence changes were observed in the
present study, including one amino acid change (S38I)
and one neutral nucleotide substitution (A798C). These
appear to be polymorphisms in RSK2, rather than dis-
ease-causing mutations.
We have screened 21 exons covering 97% of the RSK2
coding sequence and have found mutations in only 25
patients. Obviously, it is of importance to know whether
patients negative for a mutation might represent hetero-
geneity. However, for the present study there was no
formal clinical consensus on patients before they were
analyzed. As a result, available clinical data were often
incomplete or even lacking. In addition, photographs
have been obtained, to date, only for a few patients.
Therefore, and also because some of the patients with
no identified mutation may be mutated in regions of the
RSK2 gene that have not yet been explored (e.g., in exon
1, in introns away from exon-intron boundaries, or in
regulatory elements), the question of heterogeneity was
not examined in this study and, thus, remains open. To
address this question, further studies (as a first step, the
screening exon 1 of the RSK2 gene and the collection
of additional clinical data) are necessary. To this end, a
detailed questionnaire for standardized clinical data is
now systematically sent to the clinicians. Finally, it is of
interest to note that we found three mutations in female
probands who were ascertained through learning disa-
bility and mild but suggestive physical phenotype but
who had no affected male relatives.
Results from the present study, coupled with data on
previously reported mutations (Trivier et al. 1996; Mer-
ienne et al. 1998), bring the total of different mutations
to 34, illustrating allelic heterogeneity (fig. 1); the vast
majority are point mutations, with only 6 (16%) oc-
curring in CpG dinucleotides in the coding region of the
gene; there is a total of 8 amino acid substitutions (22%),
which may be of interest for functional studies. Muta-
tions are quite evenly distributed throughout the gene,
with no obvious clustering. However, one-third of mu-
tations were found in exons 4, 5, and 9, and no mu-
tations have been found yet in exons 2, 8, 12, 16, 19,
and 21. Thirty percent of the mutations involve consen-
sus splice sites, a rate higher than the 15% observed
among all point mutations causing human diseases
(Krawczak et al. 1992). To date, in only one patient was
the mutation shown to be a large deletion detected by
Southern blot analysis (Trivier et al. 1996).
We showed that the mutation arose de novo in 11
(68%) of the 16 sporadic cases for which samples were
available from the mothers of the probands (table 4).
This rate of new mutations is twice that expected (33%)
for a severe X-linked disease in which male patients do
not reproduce. This may be explained either by a higher
mutation rate during oogenesis versus spermatogenesis
or, more likely (given mutation heterogeneity), by a de-
creased reproductive fitness in carrier females. However,
although there was no obvious selection bias in the
mothers studied, this result needs to be confirmed in
additional families.
Some clinical data were available from 17 patients
with an identified mutation (3 had amino acid substi-
tutions, and 14 had truncating mutations). No consistent
relationship was observed between the severity of clinical
phenotype and the type of the RSK2 mutations. This
may be due to the fact that all these mutations cause a
loss of function. Also, no obvious correlation was found
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Figure 1 Intron-exon structure of the human Rsk2 gene and mutations in CLS. Exons are represented as boxes and numbered “1”–“22.”
The last nucleotide position of each exon is indicated at the top. Both ATP-binding sites (ATP bs) are shown as stippled boxes (in exons 3 and
15). Within exons 9 and 18 are represented the alanine-proline-glutamine ( APE) motifs, as blackened boxes, and the putative phosphorylation
sites (Ser and Thr), as lines. The different mutations detected are shown schematically below the gene. Mutations that have been published
previously (Trivier et al. 1996; Merienne et al. 1998) are underlined.
between specific mutations and the expression of par-
ticular features. For example, three patients with non-
sense mutations and one patient with a missense mu-
tation (S227A in patient AG96, previously reported by
Trivier et al. 1996) had bilateral hearing loss, whereas
no hearing defect was documented in the remaining pa-
tients. Another feature, hyperplexia (attacks consisting
of stimulus-sensitive falling), was documented only in
three male patients carrying different truncating muta-
tions. Moreover, the phenotype of patients DZ34 (of the
present study) and AH72 (of the study by Trivier et al.
1996), who share a nonsense mutation (R558X), was
shown to vary considerably. Patient DZ34 (at the age
of 17 years) had severe kyphoscoliosis and a bilateral
hearing deficit, whereas patient AH72 (at the age of 22
years) had no hearing deficit and no kyphoscoliosis. Al-
though preliminary, these observations strongly suggest
that other environmental or genetic factors influence the
phenotypic severity of CLS.
CLS shows marked phenotypic variability and a high
rate of sporadic cases (∼70% of the patients with CLS
in our series of families with an identified mutation).
These factors can lead to diagnostic—and, hence, coun-
seling—difficulties. The identification of the CLS gene
now makes accurate post- and prenatal diagnosis in fam-
ilies possible. However, the widespread dispersion of mu-
tations and the rather large number of exons will not
facilitate mutation testing. Since most RSK2 mutations
lead to premature termination of translation and/or to
loss of phosphotransferase activity, we have been de-
veloping immunoblot and RSK2 kinase assays as rapid
(1 d) and simple diagnostic tests for CLS. Immunoblot
analysis has recently allowed us to confirm the clinical
diagnosis of CLS in 6 of 13 patients and to confirm the
results of the kinase assay in 1 additional patient; mu-
tations in the RSK2 gene subsequently have been found
in 5 of these patients (Merienne et al. 1998).
The study of mutations in RSK2 and of their rela-
tionship to the CLS phenotype is just beginning. Further
investigations will clarify the physiological function of
RSK2 and are likely to result in a deeper understanding
of this disorder.
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